FDA panel rejects Sonablate 450 HIFU device for prostate cancer
This article was originally published in Clinica
Executive Summary
A US FDA advisory panel has almost unanimously rejected SonaCare Medical’s Sonablate 450 high-intensity focused ultrasound (HIFU) device, which is designed to treat recurrent prostate cancer after radiotherapy. The panelists voted that the data with the device was not good enough to support a positive risk-benefit profile, but they suggested the company could improve their trial design and provide more data in the future.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.